Depression

>

Latest News

Johnson & Johnson Rolls Out Data From Major Depressive Disorder Portfolio at ECNP / image credit ©KieferPix/Shutterstock.com
Johnson & Johnson Rolls Out Data From Major Depressive Disorder Portfolio at ECNP

October 10th 2025

Clinical and real-world data are on deck for lumateperone, seltorexant, and esketamine to treat major depressive disorder and treatment-resistant depression.

Precision Medicine Protocol for Cognitive Decline Also Reduces Depression, New Data Suggest image credit ©Maxim/stock.adobe.com
Precision Medicine Protocol for Cognitive Decline Also Reduces Depression, New Data Suggest

October 3rd 2025

Lipocene Updates Progress on Phase 3 Clinical Trial in Postpartum Depression with LPCN 1154 / image courtesy of Lipocene
Lipocine Updates Progress on Phase 3 Clinical Trial in Postpartum Depression with LPCN 1154

October 1st 2025

NeuroStim Announces Single-Day TMS Protocol With High Remission Rates in Depression / image credit ©PATTARAWIT/stock.adobe.com
NeuroStim Announces Single-Day TMS Protocol With High Remission Rates in Depression

August 26th 2025

Risk of Major Depressive Disorder Spikes Following a Medical Diagnosis, Endures for Decades  / image credit ©Justlight/stock.adobe.com
Risk of Major Depressive Disorder Spikes Following a Medical Diagnosis, Endures for Decades: New Data

August 20th 2025

More News


Site Logo

Effective Pharmacological Treatment Options for Anxiety Disorders

March 1st 2008

Cumulative research with animal, normative, and clinical populations over several decades shows that the mechanisms underlying anxiety disorders differ from those of the normal emotion of anxiety. In persons with anxiety disorders, fear and tension are disproportionate to the actual threat and may be present when no real threat exists, thereby generating an expectation of danger and distorted perceptions related to danger and various types of threats. The most common anxiety disorders are social anxiety disorder (SAD), generalized anxiety disorder (GAD), and posttraumatic stress disorder (PTSD). Persons with SAD can experience a wide range of social fears as well as severe functional consequences, whereas persons with GAD tend to experience emotional, interpersonal, and somatic symptoms of high levels of chronic anxiety. Persons with PTSD have vivid memories of and thoughts about a terrifying event or ordeal that lead to the development of anxiety, depression, and functional impairment. Effective treatment options-pharmacotherapy; psychotherapy, particularly cognitive-behavioral therapy; or a combination-can be discussed openly with the patient to make a collaborative, informed decision. A variety of medications can be used to successfully manage anxiety disorders, of which SSRIs and serotonin-norepinephrine reuptake inhibitors are the most effective. When properly used, medications can enhance a patient's own efforts to master anxiety; overcome fearful avoidance; and address troubling behaviors, patterns, or memories. (Drug Benefit Trends. 2008;20:101-113)

© 2025 MJH Life Sciences

All rights reserved.